In view of our findings, co-targeting of CR, a direct activator of the FAK signaling pathway, in combination with other key signaling pathways, such as Wnt, may be considered as a potential new strategy aimed at improving the current therapeutic landscape of MM. The gene discussed is PTK2; the disease is Miyoshi myopathy.